Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Rheumatol Int ; 39(4): 715-722, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30415453

RESUMO

Osteoarthritis (OA) is the most prevalent rheumatic disease and is a leading cause of decreased quality of life (QoL). The OA Quality of Life questionnaire (OAQoL) is an OA-specific patient-reported outcome measures. The aim of this study was to translate and validate the original UK English version of the Osteoarthritis Quality of Life (OAQoL) questionnaire into European Portuguese. The translation of the questionnaire was carried out according to a dual panel methodology (bilingual panel followed by lay panel). This was followed by cognitive debriefing interviews (CDIs) with OA patients to assess comprehension and relevance of the translated questionnaire. Finally, a validation survey was conducted to assess its psychometric properties. The Portuguese OAQoL, a comparator scale (the Nottingham Health Profile-NHP) as well as questions relating to demographic and disease information were administered to OA patients. A sub-sample of patients also completed the Portuguese OAQoL two weeks later, to assess test-retest reliability. The internal consistency, construct validity and known group validity (according to perceived OA severity) of the scale was also assessed. Both the bilingual and lay panels consisted of five individuals and no major difficulties relating to the translation process were identified. A total of ten patients with OA participated in the CDIs. The mean time to complete the questionnaire was 5 min. These interviews revealed that the Portuguese version of the OAQoL was clear, relevant and easy to complete. Finally, 53 OA patients (44 females; mean age of 67.6 years) completed the validation survey. Cronbach's alpha coefficient was 0.87, demonstrating high internal consistency. Test-retest reliability, assessed by Spearman's rank correlation coefficient, was 0.86. Moderate correlations were found with the majority of the NHP sections, providing evidence of construct validity. Significant differences in OAQoL scores were found between patients who differed according to their perceived OA severity, providing evidence of known group validity. The Portuguese version of the OAQoL is a valid and reliable questionnaire that can be used to assess QoL in OA, both in clinical practice and for research purposes.


Assuntos
Osteoartrite/fisiopatologia , Qualidade de Vida , Idoso , Assistência à Saúde Culturalmente Competente , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Osteoartrite/psicologia , Medidas de Resultados Relatados pelo Paciente , Portugal , Índice de Gravidade de Doença , Inquéritos e Questionários , Traduções
2.
Clin Exp Rheumatol ; 36 Suppl 114(5): 96-102, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30296975

RESUMO

Imaging is increasingly recognised as an essential element in the management of several rheumatologic conditions. Ultrasound is in widespread use as a safe, reproducible, and directly interpretable method for diagnosis and evaluation of arthritis and increasingly of large-vessel vasculitis (LVV). Indeed, the diagnosis and management of LVV are being transformed through the use of imaging. Increasing and more standardised evidence is being produced on the role of colour duplex sonography in the management of LVV. Nonetheless, some controversies and unresolved issues remain. This review describes current findings and reviews future perspectives in the use of ultrasound for the diagnosis and management of LVV.


Assuntos
Artéria Axilar/diagnóstico por imagem , Reumatologia/métodos , Artérias Temporais/diagnóstico por imagem , Ultrassonografia/métodos , Vasculite/diagnóstico por imagem , Humanos , Valor Preditivo dos Testes , Prognóstico , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Vasculite/terapia
3.
Acta Reumatol Port ; 42(2): 127-140, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28535545

RESUMO

BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents. OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009. METHODS: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations. RESULTS: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment. CONCLUSION: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.


Assuntos
Antirreumáticos/uso terapêutico , Metotrexato/uso terapêutico , Doenças Reumáticas/tratamento farmacológico , Humanos , Portugal , Guias de Prática Clínica como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA